Nonalcoholic Fatty Liver Disease

Abnormal glucose tolerance, especially prediabetes, was highly prevalent among children and adolescent patients with established nonalcoholic fatty liver disease, according to a recently published study.

Liver disease in children and adolescents takes on as many forms as in adults, including viral hepatitis, autoimmune diseases, fatty liver disease, and even the pediatric-specific biliary atresia that occurs in infants.

Interim results of an ongoing phase 1 clinical trial of TERN-201, a semicarbazide-sensitive amine oxidase inhibitor for the treatment of nonalcoholic steatohepatitis, revealed a positive safety and tolerance profile, according to a press release from Terns Pharmaceuticals.

Use of an automated investigation algorithm known as intelligent liver function testing increased liver disease diagnoses and improved patient quality of care in a cost-effective manner, according to a study published in Journal of Hepatology.

89Bio launched a proof of concept phase 1b/2a clinical trial of BIO89-100 for the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis with the first patient screened, according to a press release.

Adults with overweight or obesity assigned to an 8-week diet that included muffins made with palm oil experienced an increase in liver fat and circulating ceramides that was not observed in similar adults who ate muffins with sunflower oil during the same period, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Light to moderate alcohol intake correlated with a decreased risk for simple hepatic steatosis in patients without nonalcoholic fatty liver disease, whereas the same consumption in those with nonalcoholic fatty liver disease and those with obesity had an increased risk, according to recently published data.

HistoIndex and the Institute of Liver and Biliary Sciences jointly launched a center of excellence in India to aid diagnostics and clinical trials for the treatment of nonalcoholic steatohepatitis, according to a press release.

Even without a diagnosis of nonalcoholic fatty liver disease, adults with metabolically healthy obesity are nearly twice as likely to develop diabetes as those considered to have metabolically healthy normal weight, according to data published in Diabetes Metabolism Research Reviews.

Ascletis Pharma together with Sagimet Biosciences received investigational new drug approval from the National Medical Products Administration for ASC40, its therapeutic candidate for the treatment of nonalcoholic steatohepatitis, according to a press release.